Clinical Trial

A Phase 1, Open-Label Study of LY5830966, a Type II JAK2 Inhibitor, in Patients With Myelofibrosis Previously Treated With a Type I JAK2 Inhibitor, JAK2 Inhibitor-Naïve Myelofibrosis, or High-risk Relapsed/Refractory Polycythemia Vera

Cancer Type

Leukemia, Myeloma, and Hematologic

Protocol Number

202406132

Principal Investigator

Oh, Stephen

For more information contact us here:

Brief Summary

Protocol Interventions

Learn About Clinical Trials

Clinical trials are research studies that help us find new ways to prevent, diagnose, and treat cancer. If you are interested in participating in a clinical trial, our team will help you find a study that is right for you. Call us to speak with a Siteman care coordinator.